Lucid Diagnostics Inc. (NASDAQ:LUCD) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Lucid Diagnostics Inc. (NASDAQ:LUCD) has received an average recommendation of “Moderate Buy” from the five ratings firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $3.9375.

LUCD has been the topic of a number of research analyst reports. Needham & Company LLC restated a “buy” rating and set a $3.00 price objective on shares of Lucid Diagnostics in a report on Thursday, November 13th. Ascendiant Capital Markets increased their target price on Lucid Diagnostics from $8.00 to $8.25 and gave the stock a “buy” rating in a report on Wednesday, December 10th. Wall Street Zen upgraded Lucid Diagnostics from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lucid Diagnostics in a research report on Monday, December 29th.

Lucid Diagnostics Stock Performance

Shares of LUCD stock opened at $1.40 on Friday. Lucid Diagnostics has a 52 week low of $0.95 and a 52 week high of $1.80. The company’s 50 day moving average price is $1.24 and its two-hundred day moving average price is $1.17. The company has a market capitalization of $192.75 million, a P/E ratio of -1.35 and a beta of 1.18.

Institutional Trading of Lucid Diagnostics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Centiva Capital LP bought a new stake in shares of Lucid Diagnostics in the third quarter worth $25,000. Sprott Inc. acquired a new stake in Lucid Diagnostics in the 3rd quarter valued at $25,000. SG Americas Securities LLC bought a new stake in Lucid Diagnostics during the 3rd quarter worth about $26,000. Quadrature Capital Ltd acquired a new position in shares of Lucid Diagnostics during the 2nd quarter worth about $29,000. Finally, Abel Hall LLC acquired a new position in shares of Lucid Diagnostics during the 4th quarter worth about $33,000. 74.01% of the stock is currently owned by institutional investors and hedge funds.

Lucid Diagnostics Company Profile

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.